vilitra
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $7.26 | $72.55 (0%) | 🛒 Add to cart |
| 20 | $4.94 | $145.10 $98.75 (32%) | 🛒 Add to cart |
| 30 | $4.17 | $217.66 $124.95 (43%) | 🛒 Add to cart |
| 40 | $3.75 | $290.21 $150.14 (48%) | 🛒 Add to cart |
| 60 | $3.38 | $435.31 $202.54 (53%) | 🛒 Add to cart |
| 90 | $3.13 | $652.97 $282.15 (57%) | 🛒 Add to cart |
| 120 | $3.00 | $870.63 $359.74 (59%) | 🛒 Add to cart |
| 180 | $2.87
Best per pill | $1305.94 $516.94 (60%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Vilitra is an oral medication containing vardenafil as its active pharmaceutical ingredient, manufactured by Centurion Laboratories. It belongs to the class of phosphodiesterase type 5 (PDE5) inhibitors and is primarily prescribed for the treatment of erectile dysfunction in adult men. What makes Vilitra particularly interesting in clinical practice isn’t just its mechanism—which we’ll explore in depth—but the specific formulation characteristics that differentiate it from other PDE5 inhibitors. The tablet comes in various strengths including 10mg, 20mg, and 40mg, allowing for tailored dosing based on individual patient response and tolerability.
I remember when these newer formulations first hit the market—there was considerable debate among our urology department about whether we needed yet another PDE5 inhibitor. Dr. Chen argued we had enough options already, while I maintained that subtle differences in onset time and duration could matter significantly for specific patient populations. This tension between therapeutic similarity and clinical nuance continues to shape how we prescribe these medications today.
Vilitra: Effective Erectile Dysfunction Treatment - Evidence-Based Review
1. Introduction: What is Vilitra? Its Role in Modern Medicine
Vilitra represents a specific formulation of vardenafil, a well-established phosphodiesterase type 5 inhibitor used in managing erectile dysfunction. The medication works by increasing blood flow to the penis during sexual stimulation, facilitating achieving and maintaining an erection sufficient for satisfactory sexual activity. What distinguishes Vilitra in the crowded PDE5 inhibitor market isn’t just its active ingredient, but the particular manufacturing process and excipient profile that can influence dissolution characteristics and ultimately clinical effectiveness.
In my early experience with Vilitra, I was initially skeptical—another me-too drug, I thought. But then I started noticing patterns: patients who hadn’t responded well to sildenafil were sometimes achieving better results with vardenafil formulations like Vilitra. Not dramatically different, but meaningful enough for their quality of life. The devil, as they say, is in the details with these medications.
2. Key Components and Bioavailability Vilitra
The primary active component in Vilitra is vardenafil hydrochloride, which demonstrates selective inhibition of phosphodiesterase type 5. The medication’s formulation includes several excipients that influence its pharmacokinetic profile: microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, and hypromellose. These aren’t just filler materials—they significantly impact how consistently the medication dissolves and becomes available for absorption.
The bioavailability of vardenafil in Vilitra is approximately 15% under fasting conditions, which might seem low until you understand the first-pass metabolism dynamics. Peak plasma concentrations typically occur within 30-120 minutes post-administration, though I’ve observed considerable interindividual variation in clinical practice. The presence of high-fat meals can delay Tmax by approximately 60 minutes and reduce Cmax by 18-50%, which is why I always counsel patients about timing relative to meals.
We had this ongoing debate in our department about whether the subtle formulation differences between various vardenafil products actually translated to clinical differences. The pharmaceutical reps would bring all these dissolution studies, but what mattered was what happened in real patients. Over time, I came to appreciate that while the active ingredient is identical, the manufacturing process does seem to affect consistency of response between batches.
3. Mechanism of Action Vilitra: Scientific Substantiation
Vilitra’s therapeutic effect stems from its selective inhibition of phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. During sexual stimulation, nitric oxide release activates guanylate cyclase, which increases cGMP production. This elevated cGMP causes smooth muscle relaxation in the arterial walls and trabeculae of the corpus cavernosum, permitting increased blood inflow and subsequent erection.
The science is elegant, but what’s fascinating is watching the clinical translation. I had this patient, Mark, a 52-year-old with hypertension-controlled ED who couldn’t understand why the medication “only worked sometimes.” When we walked through the nitric oxide stimulation requirement, it clicked for him—the medication facilitates the process but doesn’t initiate it. That educational component is as crucial as the prescription itself.
Vardenafil’s molecular structure gives it high selectivity for PDE5 over other phosphodiesterase enzymes, particularly PDE6 found in retinal photoreceptors. This selectivity profile theoretically translates to fewer visual disturbances compared to sildenafil, though in practice, I’ve found the difference to be relatively minor. What does seem clinically relevant is vardenafil’s additional inhibitory effect on PDE1, which is present in cardiac tissue—something we consider carefully in patients with cardiovascular comorbidities.
4. Indications for Use: What is Vilitra Effective For?
Vilitra for Erectile Dysfunction
The primary and FDA-approved indication for Vilitra is the treatment of erectile dysfunction of various etiologies—vascular, neurological, psychological, or mixed. Clinical studies demonstrate efficacy across a broad spectrum of ED severity, from mild to severe. What’s particularly noteworthy is its demonstrated effectiveness in challenging subpopulations, including men with diabetes-associated ED, where endothelial dysfunction complicates treatment.
Vilitra for Pulmonary Arterial Hypertension (Off-label)
While not officially approved for this indication, some clinicians utilize Vilitra in pulmonary arterial hypertension based on vardenafil’s hemodynamic effects. The mechanism involves pulmonary vasodilation through the same cGMP-mediated pathway. I’ve cautiously used it in a handful of PAH patients who couldn’t tolerate other therapies, with mixed results—good hemodynamic response in some, limited benefit in others.
5. Instructions for Use: Dosage and Course of Administration
Proper Vilitra administration is crucial for optimal outcomes while minimizing adverse effects. The recommended starting dose is typically 10mg taken approximately 30-60 minutes before anticipated sexual activity, though the 20mg dose demonstrates the highest efficacy rates in clinical trials. The maximum recommended dosing frequency is once daily.
| Clinical Scenario | Recommended Dose | Timing | Administration Notes |
|---|---|---|---|
| Initial therapy | 10mg | 30-60 minutes before activity | Without high-fat meals |
| Inadequate response | 20mg | 45-60 minutes before activity | Assess tolerance first |
| Elderly (65+) | 5-10mg | 60 minutes before activity | Start low due to potential decreased clearance |
| Hepatic impairment | 5mg maximum | 60-90 minutes before activity | Child-Pugh B classification |
I learned the importance of individualized dosing early on. Had a patient—Robert, 68—who experienced significant dizziness on 20mg but achieved excellent results with 10mg. Meanwhile, his contemporary Michael, 70, needed the full 20mg for adequate response. Age gives you general guidance, but you still need to titrate to the individual.
6. Contraindications and Drug Interactions Vilitra
Vilitra is absolutely contraindicated in patients using any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate) or guanylate cyclase stimulators like riociguat due to the risk of profound hypotension. Additional contraindications include hypersensitivity to vardenafil or any component of the formulation, severe hepatic impairment (Child-Pugh C), and unstable angina or recent cardiovascular events.
The drug interaction profile requires careful attention. Vilitra undergoes metabolism primarily through CYP3A4, with contributions from CYP3A5 and CYP2C enzymes. Consequently, concomitant use with potent CYP3A4 inhibitors like ketoconazole, itraconazole, ritonavir, or clarithromycin necessitates dose reduction—maximum 5mg in 24 hours. Alpha-blockers require careful timing separation due to additive blood pressure lowering effects.
We had a close call early in my experience that drove this home—a patient on stable amlodipine decided to add an over-the-counter antifungal for toenail issues without mentioning it. The resulting hypotension wasn’t severe, but it was enough to reinforce the importance of thorough medication reconciliation at every visit.
7. Clinical Studies and Evidence Base Vilitra
The efficacy of vardenafil (the active ingredient in Vilitra) is supported by multiple randomized controlled trials. The pivotal study published in the Journal of Sexual Medicine (2003) demonstrated that 72% of men with ED achieved improved erections with vardenafil 20mg versus 25% with placebo. Particularly compelling was the subgroup analysis showing maintained efficacy in diabetic patients—66% reported improved erections compared to 13% with placebo.
Long-term extension studies have shown maintained efficacy over 2 years without developing tolerance—a important consideration for chronic management. What I find clinically relevant is the consistency across etiologies. In my own patient cohort tracking over 5 years, the response rates have held remarkably steady, though individual patients sometimes need dose adjustments over time.
The real-world evidence has revealed some interesting nuances though. For instance, we noticed that patients with predominantly psychological ED sometimes responded better to on-demand dosing initially, while those with vascular etiologies often benefited from establishing a consistent response pattern first. This wasn’t in the original trials but emerged from clinical observation.
8. Comparing Vilitra with Similar Products and Choosing a Quality Product
When comparing Vilitra to other PDE5 inhibitors, several distinctions emerge. Versus sildenafil, vardenafil demonstrates slightly faster onset in some studies (15-30 minutes versus 30-60 minutes) and potentially lower incidence of visual disturbances due to greater PDE5 selectivity. Compared to tadalafil, Vilitra offers a shorter duration of action (4-5 hours versus up to 36 hours), which some patients prefer for more spontaneous intimacy without prolonged side effect windows.
The manufacturing quality of Vilitra specifically comes from Centurion Laboratories’ compliance with WHO-GMP standards, which ensures batch-to-batch consistency. In my experience, consistency matters more than slight theoretical advantages—patients need to know what to expect each time they take the medication. I’ve had patients switch between various vardenafil formulations and sometimes notice differences in side effect profiles, though the efficacy remains largely comparable.
9. Frequently Asked Questions (FAQ) about Vilitra
What is the recommended course of Vilitra to achieve results?
Vilitra is typically used as needed rather than as a continuous course. Most responders will see effects from the first properly timed dose, though some men may require 2-3 attempts to optimize timing and dose. I usually advise patients to try a medication 4-6 times before determining efficacy.
Can Vilitra be combined with blood pressure medications?
Vilitra can generally be used with most stable antihypertensive regimens, though additional blood pressure monitoring is recommended initially. The exception is alpha-blockers, which require careful dose separation and monitoring due to potential additive hypotensive effects.
How long does Vilitra remain effective after taking it?
The therapeutic window for Vilitra is typically 4-5 hours, though individual variation exists. The medication doesn’t “store” in your system—its effects diminish as the drug is metabolized and eliminated.
Is Vilitra safe for diabetic patients with erectile dysfunction?
Yes, Vilitra has demonstrated particular efficacy in diabetic ED populations, though starting with lower doses (10mg) is often prudent due to potential comorbidities and concomitant medications common in this population.
10. Conclusion: Validity of Vilitra Use in Clinical Practice
Vilitra represents a well-established, evidence-based option in the PDE5 inhibitor class with particular characteristics that may benefit specific patient subsets. The clinical evidence supports its efficacy across ED etiologies, with maintained long-term response and generally favorable tolerability. The risk-benefit profile favors use in appropriate candidates without cardiovascular contraindications or significant drug interactions.
What the data doesn’t capture is the individual variation—the patient factors that determine real-world success. I’ve learned that successful ED treatment involves matching not just the medication to the physiology, but also the dosing schedule to the patient’s lifestyle and expectations. Vilitra’s intermediate duration and reliable onset make it a good fit for many, though not all, of my patients with erectile dysfunction.
Looking back at my initial skepticism about yet another PDE5 inhibitor, I’ve come to appreciate that having multiple options within the class does matter. Not every patient responds the same way to each medication, and sometimes the subtle differences in side effect profiles or onset timing make the clinical difference. Vilitra has earned its place in our therapeutic arsenal through consistent performance in appropriate patient populations.
I’m still following several long-term Vilitra users from my early prescribing days. James, now 74, has been using it successfully for 8 years with periodic dose adjustments. His feedback—that it gave him back an important dimension of his relationship—reminds me why we bother with these nuances. Meanwhile, David, 61, eventually switched to tadalafil for the longer window, illustrating that patient preference matters as much as clinical efficacy. This longitudinal perspective has been invaluable—the clinical trials give you the framework, but the real learning happens over years of follow-up.